-$0.12 Earnings Per Share Expected for Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) This Quarter

Equities analysts expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to report earnings per share of ($0.12) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals posted earnings per share of ($0.21) during the same quarter last year, which would indicate a positive year over year growth rate of 42.9%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 3rd.

According to Zacks, analysts expect that Aerpio Pharmaceuticals will report full-year earnings of ($0.58) per share for the current year. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.41) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Aerpio Pharmaceuticals.

NYSE:ARPO remained flat at $$0.65 during midday trading on Friday. 89,200 shares of the company were exchanged, compared to its average volume of 371,097. The business’s 50-day simple moving average is $0.64 and its two-hundred day simple moving average is $0.62. Aerpio Pharmaceuticals has a 1 year low of $0.45 and a 1 year high of $4.25.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Featured Article: Balance Sheet

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.